This article is more than 5 years old. Information may no longer be current.
Top stories in hematology/oncology: FDA approves Doptelet for chronic immune thrombocytopenia, race-matched liver transplants improve survival
Click Here to Manage Email Alerts
Among the top stories in hematology/oncology last week were the FDA expanding the approval of avatrombopag to include treatment of adults with chronic immune thrombocytopenia who had insufficient response to previous treatment and a Q&A focusing on race-matched liver transplants that improved survival for black patients with hepatocellular carcinoma.
Other highlights included a study that suggested certain birth defects may increase risk for childhood cancer, a study that found patients with small, node-negative, triple-negative breast cancer treated with adjuvant chemotherapy experienced survival benefits and research that determined the combination of margetuximab and chemotherapy prolonged progression-free survival among patients with human epidermal growth factor receptor 2-metastatic breast cancer.
FDA approves Doptelet for chronic immune thrombocytopenia
The FDA expanded the approval of avatrombopag to include treatment of adults with chronic immune thrombocytopenia who had insufficient response to previous treatment. Read more.
Race-matched liver transplants improve survival for black patients with hepatocellular carcinoma
Race-matched liver transplants significantly improved overall survival among black patients with early hepatocellular carcinoma, according to study results published in Journal of the American College of Surgeons. Read more.
Birth defects linked to increased risk for childhood cancer
Certain birth defects appeared significantly associated with increased risk for childhood cancer, according to results of a population-based cohort study of more than 10 million births published in JAMA Oncology. Read more.
Adjuvant chemotherapy demonstrates survival benefit in triple-negative breast cancer subtype
Patients with small, node-negative, triple-negative breast cancer treated with adjuvant chemotherapy experienced improvements in overall survival and breast cancer specific-survival, according to a study. Read more.
Margetuximab improves progression-free survival in HER2-positive metastatic breast cancer
The combination of margetuximab and chemotherapy prolonged progression-free survival compared with trastuzumab-chemotherapy among patients with human epidermal growth factor receptor 2-metastatic breast cancer progressing after treatment with trastuzumab, pertuzumab and chemotherapy, according to trial results. Read more.